A new factory in Abu Dhabi will start manufacturing a COVID-19 vaccine from Sinopharm later this year under a joint venture between the Chinese pharmaceutical giant and Abu Dhabi-based technology company Group 42.
The plant, which is being built in the Khalifa Industrial Zone of Abu Dhabi, will have a production capacity of 200 million doses a year.
The vaccine will be called Hayat-Vax when manufactured in the United Arab Emirates, but is the same inactivated vaccine from the Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group, that the UAE approved for general use in December.
As part of the joint venture, interim production of Hayat-Vax already begun in the emirate of Ras al-Khaimah under a deal between G42 and Gulf Pharmaceutical Industries.
That interim production line has an initial capacity of 2 million doses per month.The UAE hosted Phase III clinical trials of the Sinopharm vaccine in July.